Always putting healthier
lives first
scroll
News
-
Sawai Group Reports FY2021 Financial Results
-
Sawai Group Reports Third Quarter FY2021 Financial Results
-
Posted the Supplementary Document Associated with Conclusion of Asset Transfer (Acquisition) Agreement
-
Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-
-
Sawai Group Reports First Half of FY2021 Financial Results
-
Sawai Receives Approvals for Seven Generic Drugs with 14 Strengths
-
Sawai Announces Listing of Five Generic Drugs with Nine Strengths
-
Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-
-
Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
-
Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP
-
FY2021 Financial Results（Webcast）
-
FY2021 Financial Results Presentation Material
-
FY2021 Financial Results
-
Sawai Group Holdings Announces Recording of Impairment Loss of Assets Related to U.S. Segment and Gain on Bargain Purchase and Revision to Forecast of Business Results
-
Sawai Group Holdings’ Group Company Completes Succession of Kobayashi Kako’s Production Assets and Personnel of Related Divisions
Company Information
